**Authorship, Acknowledgement and Funding statements for BADBIR publications**

# **Authorship**

For all authorship, our suggestion is that authors discuss authorship (for example, first and senior authorship) before writing the paper, using the I[CMJE criteria for authorship](https://www.icmje.org/recommendations/browse/roles-and-responsibilities/defining-the-role-of-authors-and-contributors.html#two) and the [CREDIT taxonomy](https://credit.niso.org/). These require you to give detailed description of the contribution made by each author to ensure equality and consensus.

BADBIR publications may fall into one of the three following categories and will require the inclusion of the appropriate author listing and acknowledgement statement as listed below:

**1**. **For publications reporting work done by the authors where at least one author is part of the Steering Committee\* and the research question has been approved by the Steering Committee as listed in BADBIR’s** [**active research questions**](http://www.badbir.org/Data/Publications/BADBIRResearchQuestions.pdf), please list the authors and use the acknowledgement as below:

**Authorship list**: Please list the authors who were involved as per ICMJE criteria and CREDIT taxonomy, and ‘**on behalf of the** **BADBIR Study Group’.** List the full group of authors in the acknowledgement.

\**Steering committee members should exclude themselves from authorship lists from publications that are initiated and led by pharmaceutical companies in order to preserve the independence of the Steering Committee.*

**Acknowledgement**

*This paper is published with the dataset provided by BADBIR [http://www.badbir.org/]. BADBIR is one of the largest psoriasis registries in the world with over 20,000 registrations. We are grateful to all participating centres who contribute data and to participants who consent to being part of BADBIR.*

*The BADBIR Study Group comprises the BADBIR Steering Committee and the BADBIR Data Monitoring Committee (DCM). BADBIR Steering Committee members are* [*http://www.badbir.org/Clinicians/Information/SteeringCommittee*](http://www.badbir.org/Clinicians/Information/SteeringCommittee)*. Members of the DMC are: Prof Anja Strangfeld (Chair), Dr Girish Gupta, Vera Zietemann and Richard Woolf.*

**2. For publications arising from independent investigators or BAD members who are independent of the BADBIR study group**, please follow ICMJE and CREDIT taxonomy and use the statement below:

 **Acknowledgement:**

*This paper is published with the dataset provided by BADBIR [http://www.badbir.org/]. BADBIR is one of the largest psoriasis registries in the world with over 20,000 registrations. We are grateful to all participating centres who contribute data and to participants who consent to being part of BADBIR.*

*The BADBIR Study Group comprises the BADBIR Steering Committee and the BADBIR Data Monitoring Committee (DCM). BADBIR Steering Committee members are* [*http://www.badbir.org/Clinicians/Information/SteeringCommittee*](http://www.badbir.org/Clinicians/Information/SteeringCommittee)*. Members of the DMC are: Prof Anja Strangfeld (Chair), Dr Girish Gupta, Vera Zietemann and Richard Woolf.*

**3. For publications by pharmaceutical companies who are involved with BADBIR and are publishing an independent study**, please use the following statement:

**Acknowledgement**

*This paper is published with the dataset provided by BADBIR [http://www.badbir.org/]. BADBIR is one of the largest psoriasis registries in the world with over 20,000 registrations. We are grateful to all participating centres who contribute data to BADBIR and patients who consent to being part of BADBIR.*

## **Simplified table for authorship**

**Publications arising out of BADBIR data set may fall into any one of the three following categories.**

|  |  |  |
| --- | --- | --- |
|  | **Publication category** | **Acknowledgment** |
| **1** | **For publications based on BADBIR’s** [**active research questions**](http://www.badbir.org/Data/Publications/BADBIRResearchQuestions.pdf) **list\*** | Use ‘on behalf of BADBIR Study Group’ for authorship and list full group in the acknowledgement. |
| **2** | **For publications arising from independent investigators or BAD members\*** | No need to use on behalf of and only use the acknowledgement statement. |
| **3** | **For publications by pharmaceutical companies who are involved with BADBIR and are publishing an independent study**, | Please use the following acknowledgement **Acknowledgment***This paper is published with the dataset provided by BADBIR [http://www.badbir.org/]. BADBIR is one of the largest psoriasis registries in the world with over 20,000 registrations. We are grateful to all participating centres who contribute data to BADBIR and patients who consent to being part of BADBIR.* |

*\**Use the following acknowledgement statement for 1 and 2.

 \***Acknowledgement**

*This paper is published with the dataset provided by BADBIR [http://www.badbir.org/]. BADBIR is one of the largest psoriasis registries in the world with over 20,000 registrations. We are grateful to all participating centres who contribute data and to participants who consent to being part of BADBIR.*

*The BADBIR Study Group comprises the BADBIR Steering Committee and the BADBIR Data Monitoring Committee (DCM). BADBIR Steering Committee members are* [*http://www.badbir.org/Clinicians/Information/SteeringCommittee*](http://www.badbir.org/Clinicians/Information/SteeringCommittee)*. Members of the DMC are: Prof Anja Strangfeld (Chair), Dr Girish Gupta, Vera Zietemann and Richard Woolf.*

# **Funding statement**

The following funding statement should be used for all BADBIR papers irrespective of the type of study.

*British Association of Dermatologists Biologic Register Ltd (BADBRL) is a registered company within the British Association of Dermatologists (BAD) and funds the Biologics & Immunomodulators Register (BADBIR) study.  BADBIR is coordinated by the University of Manchester as research sponsor. BADBRL receives income from AbbVie, Almirall, Bristol Myers Squibb, Boehringer Ingelheim, Eli Lilly, Janssen Cilag, Leo Pharma, Novartis, Samsung Bioepsis and UCB for providing pharmacovigilance services. All decisions concerning analysis, interpretation and publication are made independently of any industry contribution. All relevant information regarding serious adverse events mentioned in this publication has been reported to the appropriate company as per the contractual agreements/standard operating procedures.*

# **Data availability statement**

Restrictions apply to the availability of these data due to patient consent and licencing agreements; data were used under license for this study. The authors therefore cannot make these data publicly available.